Tus-Pharmaceutical Group Past Earnings Performance
Past criteria checks 1/6
Tus-Pharmaceutical Group has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 9.4% per year. Tus-Pharmaceutical Group's return on equity is 1.4%, and it has net margins of 2.7%.
Key information
7.8%
Earnings growth rate
7.8%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 9.4% |
Return on equity | 1.4% |
Net Margin | 2.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Tus-Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 381 | 10 | 177 | 12 |
31 Dec 23 | 405 | 25 | 176 | 13 |
30 Sep 23 | 389 | 9 | 168 | 15 |
30 Jun 23 | 385 | 13 | 165 | 14 |
31 Mar 23 | 360 | 12 | 155 | 13 |
01 Jan 23 | 351 | 18 | 145 | 13 |
30 Sep 22 | 321 | 12 | 145 | 10 |
30 Jun 22 | 308 | 18 | 136 | 10 |
31 Mar 22 | 315 | 27 | 131 | 9 |
01 Jan 22 | 301 | 35 | 125 | 8 |
30 Sep 21 | 315 | 42 | 128 | 9 |
30 Jun 21 | 308 | 38 | 126 | 9 |
31 Mar 21 | 291 | 34 | 119 | 10 |
31 Dec 20 | 275 | 23 | 117 | 10 |
30 Sep 20 | 277 | 44 | 111 | 9 |
30 Jun 20 | 274 | 41 | 114 | 8 |
31 Mar 20 | 288 | 41 | 120 | 9 |
31 Dec 19 | 315 | 42 | 124 | 9 |
30 Sep 19 | 271 | -10 | 128 | 10 |
30 Jun 19 | 241 | -26 | 129 | 9 |
31 Mar 19 | 215 | -33 | 121 | 9 |
31 Dec 18 | 186 | -38 | 115 | 7 |
30 Sep 18 | 203 | 24 | 133 | 6 |
30 Jun 18 | 234 | 40 | 140 | 6 |
31 Mar 18 | 281 | 45 | 157 | 7 |
31 Dec 17 | 293 | 50 | 164 | 6 |
30 Sep 17 | 295 | 74 | 143 | 4 |
30 Jun 17 | 298 | 74 | 139 | 3 |
31 Mar 17 | 279 | 69 | 133 | 0 |
31 Dec 16 | 301 | 72 | 137 | 0 |
30 Sep 16 | 295 | 3 | 128 | 0 |
30 Jun 16 | 298 | 23 | 114 | 0 |
31 Mar 16 | 300 | 26 | 120 | 0 |
31 Dec 15 | 295 | 22 | 121 | 0 |
30 Sep 15 | 285 | -56 | 177 | 0 |
30 Jun 15 | 269 | -76 | 186 | 0 |
31 Mar 15 | 235 | -78 | 169 | 0 |
31 Dec 14 | 203 | -86 | 160 | 0 |
30 Sep 14 | 174 | -164 | 163 | 0 |
30 Jun 14 | 175 | -180 | 171 | 0 |
31 Mar 14 | 215 | -177 | 191 | 0 |
31 Dec 13 | 256 | -164 | 195 | 0 |
30 Sep 13 | 323 | 83 | 148 | 0 |
30 Jun 13 | 340 | 105 | 169 | 0 |
Quality Earnings: 000590 has a large one-off gain of CN¥24.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 000590's current net profit margins (2.7%) are lower than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000590 has become profitable over the past 5 years, growing earnings by 7.8% per year.
Accelerating Growth: 000590's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000590 had negative earnings growth (-15.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 000590's Return on Equity (1.4%) is considered low.